Continuing Education Activity Goto:® Alendronate is approved by the U.S. Food and Drug Administration (FDA) for the treatment of postmenopausal osteoporosis, steroid-induced osteoporosis, and male osteoporosis, as well as for the management of Paget disease of bone. Alendronate belongs to the class of bisphosphonate medications, which aids inthe prevention of bone resorption and the promotion of bone density, making ita valuable treatment for osteoporosis and various other bbone-related conditions. By binding to hydroxyapatite crystals within bone, alendronate dowwaregulates osteoelast- mediated bone reabsorption, thereby leading to a reduction in bone matrix breakdowa, Both of these mechanisms collectively contribute to regulating the reabsorption and turnover of minerals. This activity provides a comprehensive review of alendronate, including its indications, mechanism of action, specific patient populations, potential adverse effects, and the significance of monitoring during its administration. This activity also highlights the essential collaborative approach among intesprofessional healthcare professionals for the effective treatment and prevention of osteoporosis.